Merck’s Acquisition of Alydia Health

Paul Hastings advised Merck on the deal.

Merck, known as MSD outside the United States and Canada, announced a definitive agreement with Alydia Health, a commercial-stage medical device company focused on preventing maternal morbidity and mortality.

Under the terms of the agreement, Alydia will be acquired by Organon after the planned spinoff of the organization for up to $240 million total consideration, including $215 million upfront plus a $25 million contingent milestone payment.

The deal is subject to customary closing conditions and completion of Organon’s spinoff from Merck, currently scheduled in the second quarter of 2021.

The Paul Hastings team was led by M&A partner David Shine (Picture), and included partners Eric Keller, Chuck Patrizia, Todd Schneider, attorney Jason Hill, and associates Robert Dixon, Kyndle Bennett, and Ryan Enchelmayer. 




Involved fees earner: Kyndle Bennett – Paul Hastings; Robert Dixon – Paul Hastings; Ryan Enchelmayer – Paul Hastings; Jason Hill – Paul Hastings; Eric Keller – Paul Hastings; Charles Patrizia – Paul Hastings; Todd Schneider – Paul Hastings; David Shine – Paul Hastings;

Law Firms: Paul Hastings;

Clients: Merck;

Author: Martina Bellini